Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) opened at $31.18, and ended -3.43% lower at $30.11. Nearly 0.85 million shares were traded by the close, lower than its average daily volume of 1.56 million shares.ACADIA Pharmaceuticals Inc. (ACAD) Analyst Opinion
ACADIA Pharmaceuticals Inc. has a consensus outperform rating from 10 Wall Street analysts, and the number of shares currently sold short amount to at least 7.66% of shares outstanding. The stock spiked 3.76% last month and is up 4.4 this year. Wall Street is only getting more bullish on the stock, with 8 of analysts who cover ACAD having a buy-equivalent rating. Analysts have placed a $49.78 price target on ACADIA Pharmaceuticals Inc., suggesting a 65.33% gain from recent close. It’s currently trading about -26.92% below its 52-week high.ACADIA Pharmaceuticals Inc. Earnings Surprise
ACADIA Pharmaceuticals Inc. (ACAD) surprised the stock market in its last reported earnings when it earned -$0.53 a piece versus the consensus-estimated -$0.62. Its revenue totaled $32.03 million up 5.09% from the previous quarter.ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Intraday View
This stock (ACAD) is ahead of its 52-week low with 20.15%. Its last month’s stock price volatility remained 3.24% which for the week stands at 3.9%. The share price has moved forward from its 20 days moving average, trading at a distance of 1.76% and stays -2.05% away from its 50 days moving average. Over the last five days, shares have managed 4.73% gains and now is down -4.99% since hitting its 200-day moving average of $31.87. ACADIA Pharmaceuticals Inc. (ACAD) has made its way to a 12-month gain of 4.58%.
Turning to Puma Biotechnology, Inc. (NASDAQ:PBYI), its shares were trading at $98.85 a retreat of $-0.95, on the trading floor. The stock, after opening at $100.55, touched a high of $100.55 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.7. Puma Biotechnology, Inc. has 4 buy ratings, 1 holds and 0 sells even after the stock tumbled -27.79% from its high of $136.90 to a $3.71 billion market value through last close.Puma Biotechnology, Inc. (PBYI) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 1.67 to 1.67 during a month. Analysts set a 12-month price target of $133.33 a share. The target implies a 34.88% spike from where the shares are currently trading. Also, the current price highlights a discount of 65.91% to analysts’ high consensus price target.Puma Biotechnology, Inc. (NASDAQ:PBYI) Intraday Trading
The counter witnessed a trading volume of 0.53 million shares versus an average volume of 0.75 million shares during last trading session. Its last month’s stock price volatility remained 2.78% which for the week approaches 5.14%. The lowest price the stock reached in the last trading day was $98.6 and compares with the $28.35 52-week low. The stock recovered 248.68% since its low point and has performed 221.99% year-to-date.